More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023 (1-7).
DNA repair gene mutations predict bladder cancer response to neoadjuvant chemotherapy
An analysis of pre-treatment tumor specimens from 105 patients with localized muscle-invasive bladder cancer found that the presence of a mutation in any one of
July 30, 2024